Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Research and Development Expenses

v3.24.3
Note 14 - Research and Development Expenses
9 Months Ended
Sep. 30, 2024
Notes to Financial Statements  
Research, Development, and Computer Software Disclosure [Text Block]

NOTE 14: RESEARCH AND DEVELOPMENT EXPENSES 

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2024

   

2023

   

2024

   

2023

 

Salary and employee benefits

  $ 711     $ 317     $ 1,154     $ 571  

Consultants and subcontractors

    100       25       177       48  

Depreciation

    4       -       8       -  

Clinical trials

    -       -       -       19  

Expenses - other

    63       50       178       74  

Total

  $ 878     $ 392     $ 1,517     $ 712